CEBPA and erythema multiforme: While mutations of CEBPA were associated with significantly decreased odds of EM AML in our cohort, this effect was not seen individually in biallelic mutations of CEBPA, CEBPA-TAD or CEBPA-bZIP, rendering the mechanism unclear and thereby calling for more detailed investigations as subtypes of CEBPA have been reported to show differences in clinical outcomes [18].